Skip to main content
David Carbone, MD, Oncology, Columbus, OH, Ohio State University Wexner Medical Center

DavidCarboneMDPhD

Oncology • Columbus, OH

Thoracic Cancer

Director, Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute & Professor of Medicine, The Ohio State University

Join to view full profile

Dr. Carbone is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Carbone's full profile

Already have an account?

Summary

  • I am a Professor of Internal Medicine, Director of the James Thoracic Oncology Center at the OSUMC and
    holds the Barbara J. Bonner Chair in Lung Research. I graduated summa cum laude from Amherst College
    in 1977 and received an MD and PhD in Molecular Biology and Genetics at Johns Hopkins University in 1985. I then did an Internal Medicine internship and residency at Johns Hopkins Hospital through 1988 followed by a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. At Vanderbilt, I was Professor of Medicine, Cell Biology, and Cancer Biology, and Director of the Thoracic/Head and Neck Cancer Program, Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer for 11 years and PI of the Strategic Partnering to Evaluate Cancer Signatures (SPECS) in Lung Cancer UO1 consortium. I was recruited to The Ohio State University in 2012 to direct the James Thoracic Oncology Center. My research interests, grant support and publications have been focused on lung cancer, and specifically proteomic and expression array signature development, lung cancer genetics, cancer immunotherapy, tumor-associated immunosuppression mechanisms. Recent research directions include development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and preneoplasias to guide the development of novel therapeutics, especially using mass spectrometry-based proteomics. I have over 200 peer-reviewed publications, books and review articles, has served on several NCI grant review panels, including the clinical program project parent committee, and have had continuous NCI funding since early in my career. I served on the Board of Scientific Counselors for the NCI, and currently I am Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and Past President of the International Association for the Study of Lung Cancer (IASLC).

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1988
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1985

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2025
  • TN State Medical License
    TN State Medical License 1996 - 2013
  • TX State Medical License
    TX State Medical License 1992 - 1997
  • MD State Medical License
    MD State Medical License 1988 - 1992
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2000

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Identifying Patterns of Care for Elderly Patients with Non-Surgically Treated Stage III Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database  
    Kai He, Terence M Williams, John C Grecula, Eric D Miller, Erin M Bertino, David P Carbone, Peter G Shields, Jose G Bazan, Karl E Haglund, Gregory A Otterson, BioMed Central
  • RANBP9 Affects Cancer Cells Response to Genotoxic Stress and Its Overexpression Is Associated with Worse Response to Platinum in NSCLC Patients  
    David Carbone, MD, Nature

Lectures

  • Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with a Major Pathological Response Rate of 20% in Resectable Stage IB–IIIB NSCLC
    Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with a Major Pathological Response Rate of 20% in Resectable Stage IB–IIIB NSCLCSeptember 16th, 2022
  • Lung Cancer Research Foundation Creates Scientific Executive Committee
    Lung Cancer Research Foundation Creates Scientific Executive CommitteeJuly 11th, 2022
  • Moving the Goal Posts for Pre-Op and Post-Op Chemotherapy for Resectable NSCLC
    Moving the Goal Posts for Pre-Op and Post-Op Chemotherapy for Resectable NSCLCJuly 8th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. David Carbone, Dr. David Carbone, MD, Dr. D Carbone